InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,732.93
(
0.25%
)
US TECH 100
19,431.14
(
0.57%
)
Dow Jones
42,208.22
(
0.20%
)
Brent Oil
74.56
(
1.12%
)
Bitcoin
64,481.51
(
1.82%
)
Post# of 253211
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120490
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 162890

Tuesday, 07/09/2013 11:26:04 AM

Tuesday, July 09, 2013 11:26:04 AM

Post# of 253211
ENTA—A phase-1b/2a monotherapy trial of EDP-239 has been started by NVS, which is the first public sign that NVS really cares about the EDP-239 program. (Source: ENTA’s JMP webcast today.) My ENTA valuation model ascribes zero value for EDP-239, so anything that does happen is all upside.

Please see #msg-89280314 for a summary of the potential milestones for ENTA from the EDP-239 program.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up